Le paludisme grave à P. falciparum en France, 2000-2011 : évolution épidémiologique et nécessité d’une nouvelle prise en charge thérapeutique

  title={Le paludisme grave {\`a} P. falciparum en France, 2000-2011 : {\'e}volution {\'e}pid{\'e}miologique et n{\'e}cessit{\'e} d’une nouvelle prise en charge th{\'e}rapeutique},
  author={Martin Danis and Marc Thellier and St{\'e}phane Jaur{\'e}guiberry and François Bricaire and Pierre Buffet},
  journal={Bulletin De L Academie Nationale De Medecine},
Changes in malaria epidemiology in France and worldwide, 2000-2015.


Severe Imported Plasmodium falciparum Malaria, France, 1996–2003
Factors independently associated with severe imported P. falciparum malaria were older age, European origin, travel to eastern Africa, absence of chemoprophylaxis, initial visit to a general practitioner, time to diagnosis of 4 to 12 days, and diagnosis during the fall-winter season.
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination.
Artesunate (10mg/kg over 3 days) plus mefloquine (25 mg/kg) is currently the most effective treatment for falciparum malaria in this area of increasing meFLoquine resistance.
Artemisinin resistance in Plasmodium falciparum malaria.
P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand, and resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing.
Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia
Post-treatment haemolysis after parenteral artesunate may be of clinical relevance in particular in imported severe malaria characterized by high parasite levels, and extended follow-up of at least 30 days including controls of haematological parameters after artes unate treatment seems to be indicated.
Severe Imported Falciparum Malaria: A Cohort Study in 400 Critically Ill Adults
In a large population of adults treated in a non-endemic industrialized country, severe malaria still carried a high mortality rate, and the data, including predictors of death, can probably be generalized to other non- endemic countries where high-quality healthcare is available.
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
Data from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity, however, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment.
Intravenous Artesunate for Severe Malaria in Travelers, Europe
In 6 patients at 5 treatment centers, a self-limiting episode of unexplained hemolysis occurred after reduction of parasitemia levels, and IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe.